Navigation Links
Measurement Challenges In Detecting Cancer Biomarkers

Effective control of sexually transmitted diseases (STDs) requires treatment of the sexual partners of infected patients. A new study shows that providing infected men with antibiotics to give their partners is more effective than traditional means of contacting and treating the partners, according to an article in the Sept. 1 issue of Clinical Infectious Diseases, now available online. Men with chlamydia or gonorrhea were more likely to see and talk to their female partners about the STD when given medicine to give to their partners than the men who were simply told to inform their partners of their STD exposure.

Partner referral is the most common method of attempting to control STD spread and recurrence. Health care providers ask STD-infected patients to contact their sexual partners, inform them of their risk for infection, and encourage them to seek medical care. A second method, booklet-enhanced partner referral, also provides the patients with booklets that have referral tear-out cards for distribution to sex partners. The new method, known as patient-delivered partner treatment, gives the patient an antibiotic to offer to his partner.

To compare the efficacy of patient-delivered partner treatment with standard and booklet-enhanced partner referral, the researchers enrolled 977 men from an STD clinic in New Orleans. The men had all had a diagnosis of urethritis due to chlamydia and/or gonorrhea infection, and most reported two or more sex partners. The men were each randomly assigned to one of the three partner treatment arms. Nearly 80 percent of the patients completed a follow-up interview four weeks later, and 38 percent were re-tested for STDs.

The researchers found that about 70 percent of men in the patient-delivered partner treatment arm gave the intervention to their partners (giving antibiotics), compared with 58 percent of men in the booklet-enhanced arm (giving tear-out referral cards), and 48 percent of men in the standard p artner referral arm (telling partners to get treated). Men in the patient-delivered partner treatment arm were also less likely than men in either of the other two arms to have unprotected sex before their partners were treated for STDs. Finally, men in the patient-delivered partner treatment and booklet-enhanced arms were far less likely than men in the standard partner referral arm to re-test positive for chlamydia and gonorrhea at follow-up.

Patient-delivered partner treatment is not yet used widely due mainly to fears that are largely unfounded, said Patricia Kissinger, PhD, of Tulane University School of Public Health and Tropical Medicine and lead author of the article. "Clinicians have fears of legal liability, particularly if the partners have side effects. In three randomized trials [on patient-delivered partner treatment] that have been conducted, there have been no reports of adverse events," Dr. Kissinger said. "Particularly for chlamydia, there is little chance of side effects with azithromycin," the antibiotic given to patients in patient-delivered partner treatment.

Another worry that clinicians may have about patient-delivered partner treatment is "that partners will not get treated and counseled for other [STDs] they may have, such as HIV" if they receive treatment for chlamydia or gonorrhea, Dr. Kissinger said. "While this is a valid concern, the alternative to not doing patient-delivered partner treatment is to rely on the patient to refer the partners. We know that that results in less than 50 percent of the partners getting treated. So those partners were probably not going to get those services anyway."

The relative success of patient-delivered partner treatment probably lies in the fact that, with the more traditional methods, patients just had to admit to their partners that there was a problem. With the new method, the patients can offer their partners a solution. "The patients really like the empowerment of being abl e to give the medicine to their partners," Dr. Kissinger said. And if it helps to prevent the spread and recurrence of STDs, patient-delivered partner treatment could be a valuable tool to add to the physician's black bag.


'"/>

Source:


Related biology news :

1. Grand Challenges in Global Health initiative funds Yale project
2. Detecting explosives with honeybees
3. Detecting microalgae in coastal waters
4. Detecting poisons in nectar is an odour-ous task for honeybees
5. Adding Radiation Therapy To Chemotherapy Improves Survival In Patients With High-risk Breast Cancer
6. Jump-starting T Cells In Skin Cancer
7. Deficient DNA Repair Capacity Associated With Increased Risk Of Breast Cancer
8. Fox Chase Cancer Center scientists identify immune-system mutation
9. Breakthrough Microarray-based Technology for the Study of Cancer
10. Yale Scientists Find MicroRNA Regulates Ras Cancer Gene
11. Fundamental Finding Yields Insight into Stem Cells, Cancer; Opens Door to Drug Discovery
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/14/2017)... Feb. 14, 2017  Wake Forest Baptist Medical Center ... new chief executive officer (CEO). Freischlag joins the medical ... D. McConnell , M.D., who last year announced that ... Medical Center, after leading it since 2008.   ... of Wake Forest Baptist,s academic health system, which includes ...
(Date:2/8/2017)... 2017 About Voice Recognition Biometrics Voice recognition ... against a stored voiceprint template. Acoustic features of ... tone are compared to distinguish between individual voices. ... most PCs already have a microphone and can ... biometrics are most likely to be deployed in ...
(Date:2/7/2017)... 2017   MedNet Solutions , an innovative SaaS-based ... clinical research, is pleased to announce that the latest ... highly flexible and award winning eClinical solution, is now ... is a proven Software-as-a-Service (SaaS) clinical research technology ... but also delivers an entire suite of eClinical tools ...
Breaking Biology News(10 mins):
(Date:2/18/2017)... ... 17, 2017 , ... The BMT Tandem Meetings of the ... Blood & Marrow Transplant Research (CIBMTR) will take place Feb. 22-26, 2017 at ... scientific sessions offer investigators, clinicians, laboratory technicians, clinical research professionals, nurses, pharmacists, administrators, ...
(Date:2/17/2017)... 2017  If only one in every hundred ... resistance to chemotherapy, thousands of cancer cells would ... on finding these mutations in ever-smaller subpopulations of ... DNA in blood — to guide treatment decisions ... Unfortunately, however, detecting these genetic anomalies may be ...
(Date:2/16/2017)... PHILADELPHIA , Feb. 16, 2017  ImMAGE Biotherapeutics (OTCMKTS: ... immune system to find a better treatment for triple negative ... Start in France program. ... is an accelerator designed to help entrepreneurs grow their business ... was one of eight American companies selected to complete an ...
(Date:2/16/2017)...   Capricor Therapeutics, Inc. (NASDAQ: ... first-in-class biological therapies for cardiac and other medical ... terminate its license agreement with the Mayo Clinic ... "Our decision to return these rights ... efforts to advance our core cell and exosome-based ...
Breaking Biology Technology: